Biotin anti-human CD267 TACI Antibody anti-CD267 - 1A1,BioLegend,311904

Host

Rat

Reactivity

Human

Application

FC - Quality tested

Platform ID

BAB856224661

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameBiotin anti-human CD267 TACI Antibody anti-CD267 - 1A1
Cat. No.311904
HostRat
RRIDAB_2240574 (BioLegend Cat. No. 311904)
IsotypeRat IgG2a, κ
ReactivityHuman
ApplicationFC - Quality tested
ClonalityMonoclonal
Clone Number1A1
Concentration0.5 mg/ml
TargetCD267
ImmunogenTACI-transfected RBL cells
PurityThe antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.